{"id":"W4417458323","doi":"10.1158/1078-0432.ccr-25-1818","title":"KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Olaparib; Chemotherapy; Breast cancer; Clinical endpoint; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008818359,0.0004618983,0.001182821,0.0002216553,0.0002226538,0.0005362069,0.0005557926,0.0005756489,0.005841686],"category_scores_gemma":[0.0007255797,0.0002503025,0.0006262404,0.0001706312,0.0003526295,0.0004572181,0.0002563222,0.001575034,0.0008500314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007500902,"about_ca_system_score_gemma":0.0009211295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006217308,"about_ca_topic_score_gemma":0.002129751,"domain_scores_codex":[0.9996914,0.0001407723,0.00002298049,0.00005823011,0.00003441778,0.00005222098],"domain_scores_gemma":[0.9996514,0.00006510135,0.00007985541,0.0000211771,0.00002233631,0.0001601589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8162826,0.0233428,0.005373479,0.0009400668,0.0008221085,0.0001310864,0.0001292476,0.0008343583,0.02302478,0.0001616625,0.002187732,0.1267702],"study_design_scores_gemma":[0.4850168,0.4742809,0.0281293,0.000126814,0.0009436736,0.000358962,0.00007343368,0.001502486,0.005248507,0.0001689296,0.004119914,0.00003023044],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949571,0.002228505,0.0001385393,0.0002901351,0.0001072805,0.0007012414,0.0003262767,0.00003943018,0.001211464],"genre_scores_gemma":[0.9961032,0.0008782479,0.0004236697,0.000267351,0.00006747597,0.0005632895,0.0003472281,0.000007603632,0.001342059],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005841686,"threshold_uncertainty_score":0.01954234,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1890318996368118,"score_gpt":0.5269343380585764,"score_spread":0.3379024384217645,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}